This is a major derisking catalyst for APGE. The Phase 2 Part B data confirms zumilokibart's best-in-class potential with robust efficacy and transformative dosing (2-4 dosing days/year vs 26 for DUPIXENT). The Blackstone financing removes equity dilution overhang. Key catalysts ahead: Phase 3 initiation 2H 2026, 52-week Part B data 1H 2027, Phase 3 readouts 2028. Monitor for regulatory feedback on Phase 3 dose and any competitive updates from Sanofi's amlitelimab.
APGE drugs
APGE drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 27 $77.75entry
- T+1 · 6mo ago +0.09%α −0.46% · $77.82
- T+5 · 6mo ago +1.23%α +0.03% · $78.71
- T+20 · 5mo ago +70.65%α +72.55% · $132.68
- T+60 · 3mo ago +73.31%α +71.43% · $134.75
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Apogee Therapeutics announced positive 16-week induction dose optimization results from Part B of the Phase 2 APEX trial of zumilokibart in moderate-to-severe atopic dermatitis. The mid-dose met all primary and secondary endpoints with high statistical significance (EASI-75 65.9% vs 23.4% placebo, p<0.001), supporting planned Phase 3 initiation in 2H 2026. The company also disclosed a strategic financing collaboration with Blackstone Life Sciences expected to provide funding through commercialization without need for future equity financing.
Key Facts
- APEX Part B met primary endpoint: mid-dose EASI-75 65.9% vs placebo 23.4% (p<0.001)
- Mid-dose secondary endpoints all met: IGA 0/1 46.0% (p<0.001), EASI-90 47.4% (p<0.001), I-NRS4 50.5% (p<0.001), EASI-100 16.5% (p<0.01), vLDA 20.6% (p<0.01)
- Mid-dose selected as planned Phase 3 dose; Phase 3 ADventure program (3 trials) expected to initiate 2H 2026
- Blackstone collaboration provides up to $1.3B in funding including $400M pre-approval and up to $400M approval tranche; max royalty rate 6.25% on up to $5B of WW annual sales
- Zumilokibart well-tolerated; pooled conjunctivitis rate 10.6% for mid-dose
- Phase 2b ASPIRE asthma trial expected 1H 2027; Phase 2a ELEVATE EoE trial expected 2H 2026
- Launch anticipated in 2029
Financial Impact
Blackstone financing provides up to $1.3B; Apogee had $1.3B cash as of March 31, 2026; total capital expected to fund through commercialization without equity financing
Risk Factors
- Phase 3 trials may fail to replicate Phase 2 results
- Competitive landscape evolving (amlitelimab, other IL-13/IL-4 agents)
- Conjunctivitis rate (10.6%) may be scrutinized by regulators
- Blackstone royalty obligation (up to 6.25% on first $5B sales) reduces peak margin
- Regulatory interactions could delay Phase 3 initiation timeline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-066572 |
| Document: tm2615568d1_8k.htm | 0001104659-26-066572 |
| Document: tm2615568d1_ex99-1.htm | 0001104659-26-066572 |
| Document: 0001104659-26-066572-index-headers.html | 0001104659-26-066572 |
| Document: 0001104659-26-066572-index.html | 0001104659-26-066572 |
| Document: 0001104659-26-066572.txt | 0001104659-26-066572 |
Track record
31 reports on APGE
8 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 11 of 12 went positive at some point.
Filters
- Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
- Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
- Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
- Aug 10, 202614w ago 8-K Bullish 8/10 No price data
- Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
- Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
- Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
- Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers